EndoAnchors按适应症应用的早期真实世界经验
单中心回顾性分析2016至2018年37例EVAR中使用Heli-FX EndoAnchor的患者,按适应症分为既往EVAR术后内漏、术中1A型内漏、高风险密封区及胸主动脉EVAR四组。术中1A型内漏与高风险密封区组技术成功率高、随访瘤囊退缩且无近端内漏;既往EVAR术后1A型内漏组仅不足半数内漏解决。
要点
- 术中1A型内漏与高风险密封区使用EA可获100%技术与手术成功并伴瘤囊退缩。
- 既往EVAR术后1A型内漏者EA术后仅45.4%内漏解决,需谨慎选择。
- 胸主动脉EVAR组出现EA栓塞至左肾动脉的不良事件,技术成功率83.3%。
核心结论
- 早期经验提示EA可有效处理术中1A型内漏和高风险密封区,随访瘤囊显著退缩且无近端内漏。
- 既往EVAR术后1A型内漏患者中不足半数在EA尝试修复后内漏解决。
研究设计与样本
- 单中心回顾性研究,回顾前瞻性维护的动脉瘤数据库,纳入2016至2018年使用Heli-FX EA行EVAR的37例患者。
- 按适应症分为四组:A组既往EVAR伴内漏(n=11)、B组术中1A型内漏(n=10)、C组高风险密封区(n=10)、D组胸主动脉EVAR(n=6)。
- 技术成功定义为EA成功释放,手术成功定义为完成主动脉造影无内漏。
主要发现
- A组均为1A型内漏,平均释放10枚EA,技术成功率100%、手术成功率45.4%,平均随访10.6个月45.4%内漏持续,主动脉相关生存100%。
- B组平均使用8.7枚EA,技术与手术成功率均100%,平均随访13.6个月瘤囊平均退缩9.75 mm且无1A型内漏。
- C组平均释放9.5枚EA,技术与手术成功率均100%,平均随访11.2个月无残留内漏、瘤囊平均退缩3.4 mm,总生存100%。
- D组平均使用8.3枚EA,技术成功率83.3%、手术成功率66.6%,平均随访9.4个月总生存83.3%、瘤囊平均增大2.2 mm。
- B组发生1例右侧髂动脉夹层(导丝操作所致,覆膜支架治疗),D组发生1例EA栓塞至左肾动脉。
关键数值与推荐
- 技术成功定义为EA成功释放,手术成功定义为完成主动脉造影无内漏。
- A组2例围手术期再干预:经腰椎线圈栓塞和近端移植物延长联合双侧肾动脉支架。
- D组技术成功率83.3%、手术成功率66.6%,平均随访9.4个月总生存83.3%。
临床怎么用
- 对术中1A型内漏和高风险密封区可考虑EA固定以促进瘤囊退缩并减少近端内漏。
- 对既往EVAR术后1A型内漏,EA术后内漏解决率不足半数,应个体化选择并准备再干预方案。
- 胸主动脉EVAR使用EA需警惕EA栓塞等不良事件,需进一步经验与更长随访确定获益人群。
局限性
- 单中心回顾性研究,样本量小(37例),各组样本量有限。
- 随访时间较短(平均9.4至13.6个月),无法评估长期结局。
- 原文未报告统计学比较或P值,组间差异需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Heli-FX EndoAnchor (EA) system is a transmural aortic fixation device with Federal Drug Administration (FDA) approval for treatment of endoleaks, endograft migration, or high-risk seal zones. Published data are primarily from industry-sponsored registries highlighting safety and efficacy. Our objective is to evaluate real-world outcomes of EA usage after FDA approval across a variety of stent grafts and indications at a single institution. METHODS: We retrospectively reviewed our prospectively maintained aneurysm database for patients undergoing endovascular aortic repair (EVAR) with Heli-FX EAs. Technical success was defined as successful EA deployment, while procedural success was defined as absence of endoleak on completion aortogram. Cohorts were divided by indication and outcomes assessed via review of clinical and radiographic data. RESULTS: From 2016 to 2018, 37 patients underwent EA fixation. We divided the cohort by indication: Group A (prior EVAR with endoleak), B (intraoperative type 1A endoleak), C (high-risk seal zone), and D (thoracic EVAR). In Group A (n = 11), all endoleaks were type 1A and a mean of 10 EAs were deployed with 100% technical and 45.4% procedural success. Two perioperative reinterventions were performed (translumbar coil embolization and proximal graft extension with bilateral renal artery stents). At a mean 10.6 months of follow-up, 45.4% of patients had persistent endoleaks, with 100% aortic-related survival. In Group B (n = 10), a mean of 8.7 EAs were used with 100% technical and procedural success. One immediate adverse event occurred (right iliac dissection from wire manipulation, treated with a covered stent). At 13.6-month mean follow-up, there was significant sac regression (mean 9.75 mm) with no type 1A endoleaks. In Group C (n = 10), a mean of 9.5 EAs were deployed with 100% technical and procedural success. At 11.2-month mean follow-up, there were no residual endoleaks and significant sac regression (mean 3.4 mm). Overall survival was 100%. In Group D (n = 6), a mean of 8.3 EAs were used with 83.3% technical and 66.6% procedural success. One immediate adverse event occurred, in which an EA embolized to the left renal artery. At 9.4-month mean follow-up, overall survival was 83.3% with a mean 2.2-mm increase in sac diameter. CONCLUSIONS: Early experience suggests that EAs effectively treat intraoperative type 1A endoleaks and high-risk seal zones, with significant sac regression and no proximal endoleaks on follow-up. In patients treated for prior EVAR with postoperative type 1A endoleaks, fewer than half resolved after EA attempted repair. Further experience and longer term follow-up will be necessary to determine which patients most benefit from postoperative EA fixation.
引用
- Ho VT, George EL, Dua A, et al. Early Real-World Experience with EndoAnchors by Indication. Ann Vasc Surg. 2019. PMID: 31201976. doi:10.1016/j.avsg.2019.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。